ImmunityBio plans to conduct clinical trials to study recombinant BCG (iBCG) and sBCG manufactured by Serum Institute in combination with Anktiva for different types of bladder and other cancers.

Government health officials detected as many as 719,000 new TB cases during a short, 100-day TB camp held last year, in ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an alternative source of Bacillus Calmette-Guerin (BCG) to treat bladder cancer.

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to ...

Credit: ImmunityBio. Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in ...